Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 3, 2006, Pages 253-257

  Dobie, Robert A ^a,c   Black, F Owen ^b   Pezsnecker, Susan C ^b   Stallings, Valerie L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEGACY RESEARCH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; GENTAMICIN;

ADULT; ARTICLE; AUDIOMETRY; AUDITORY THRESHOLD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEARING LOSS; HUMAN; MALE; PURE TONE AUDIOMETRY; SPEECH; UNITED STATES;

ADULT; AUDIOMETRY; FEMALE; GENTAMICINS; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VESTIBULAR FUNCTION TESTS; VESTIBULE;

EID: 33645238251     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.3.253     Document Type: Article

References (27)

1. Jackson GG, Arcieri G. Ototoxicity of gentamicin in man. J Infect Dis. 1971;124 (suppl 124):130-137.
2. Black FO, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol. 2004;25:559-569.
3. International Organization for Standardization. Acoustics: Determination of Occupational Noise Exposure and Estimation of Noise-Induced Hearing Impairment, ISO-1999. Geneva, Switzerland: International Organization for Standardization; 1990.
4. American National Standards Institute. Determination of Occupational Noise Exposure and Estimation of Noise-Induced Hearing Impairment, ANSI S3.44-1996. New York, NY: Acoustical Society of America; 1996.
5. Glorig A, Roberts J. Hearing Levels of Adults by Age and Sex: United States, 1960-1962. Washington, DC: US Dept of Health, Education, and Welfare; 1965. Vital and Health Statistics, Series 11. DHEW publication No. (PHS) 79-1063.
6. American Standards Association. Audiometers for General Diagnostic Purposes, ASA Z24.5-1951. New York, NY: American Standards Association; 1951.
7. American National Standards Institute. American National Standard Specifications for Audiometers, ANSI S3.6-1996. New York, NY: Acoustical Society of America; 1996.
8. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics With Confidence. London, England: BMJ Books; 2000.
9. Fletcher H. A method of calculating hearing loss for speech from the audiogram. Acta Otolaryngol Suppl. 1950;90:26-37.
10. Hoffman HJ. Hearing examination of adults (20 to 60 years old) in the National Health and Nutrition Examination Survey (NHANES), 1999-2004. Presented at: National Hearing Conservation Association; Tucson, Ariz; February 26, 2005.
11. Sixt E, Rosenhall U. Presbycusis related to socioeconomic factors and state of health. Scand Audiol. 1997;26:133-140.
12. Royster LH, Royster JD, Dobie RA. Prediction and analysis of the hearing characteristics of noise-exposed populations or individuals. In: Berger EH, Royster LH, Royster JD, Driscoll DP, Layne M, eds. The Noise Manual. Rev 5th ed. Fairfax, Va: American Industrial Hygiene Association; 2003.
13. Lutman ME, Davis AC. The distribution of hearing threshold levels in the general population aged 18-30 years. Audiology. 1994;33:327-350.
14. Lerner SA, Matz GJ. Aminoglycoside ototoxicity. Am J Otolaryngol. 1980;1:169-179.
15. Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy. Antimicrob Agents Chemother. 2001;45:2502-2509.
16. Fausti SA, Larson VD, Noffsinger D, Wilson RH, Phillips DS, Fowler CG. Highfrequency audiometric monitoring strategy for early detection of ototoxicity. Ear Hear. 1994;15:232-239.
17. Rickards FW, DeVidi S, McMahon DS. Audiological indicators of exaggerated hearing loss in noise-induced hearing loss claims. Aust J Audiol. 1996;18:89-97.
18. Meyers RM. Ototoxic effects of gentamicin. Arch Otolaryngol. 1970;92:160-162.
19. Smith CR, Lipsky JL, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980;302:1106-1109.
20. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984;149:23-30.
21. Brummett RE, Morrison RB. The incidence of aminoglycoside-induced hearing loss. Arch Otolaryngol Head Neck Surg. 1990;116:406-410.
22. Gurtler N, Schmuziger N, Kim Y, Mhatre AN, Jungi M, Lalwani AK. Audiologic testing and molecular analysis of 12S rRNA in patients receiving aminoglycosides. Laryngoscope. 2005;115:640-644.
23. Fischel-Ghodsian N, Presant TR, Chaltraw WE, et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol. 1997;18:173-178.
24. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol. 2000;5:3-22.
25. Halmagyi GM, Fattore CM, Curthoys IS, Wade S. Gentamicin vestibulotoxicity. Otolaryngol Head Neck Surg. 1994;111:571-574.
26. Longridge NS, Mallinson AI. A discussion of the dynamic illegible "E" test. Otolaryngol Head Neck Surg. 1984;92:671-677.
27. Rybak LP, Kelly T. Ototoxicity: bioprotective mechanisms. Curr Opin Otolaryngol Head Neck Surg. 2003;11:328-333.